Supriya Lifesciences, a Mumbai‑based maker of active pharmaceutical ingredients, is betting on big capacity upgrades to push its revenue to about Rs1,000 cr by the fiscal year 2027.
Revenue Growth Outlook
In the September quarter the company rebounded sharply, with revenue up 20% YoY to Rs199.8 cr and EBITDA rising 12% to Rs73 cr. Margins stayed steady at 36% and exports made up 81% of sales. The firm aims for more than 20% annual revenue growth, targeting Rs1,000 cr by FY27, up from roughly Rs706 cr in FY25.
Key Products and Diversification
Supriya’s main cash generators are three API molecules:
- Ketamine – 60‑70% of revenue
- Chlorpheniramine – 45‑55% of revenue
- Salbutamol – 30‑40% of revenue
These three account for more than half of total sales. To lower the risk of relying on a few products, the company is launching new APIs, entering contract development and manufacturing (CDMO) work, and expanding into formulations.
Capacity Expansion Plans
Two major capital projects are under way:
- Ambernath formulations facility – finalising approvals; expected to start revenue in Q4 after WHO‑GMP certification. Investment: Rs150‑160 cr.
- Greenfield plant at Patalganga – first‑phase spend of Rs350 cr over 2‑3 years. Ground‑breaking could begin next financial year. The site will produce both APIs and formulations.
Funding will mainly come from internal cash; the company remains debt‑free with about Rs150 cr in the bank.
Margin Guidance and Market Outlook
Supriya expects margins of 33‑35% going forward, helped by deeper backward integration and larger batch sizes after a 55% increase in reactor capacity. Europe and Latin America stay the biggest markets for now, while North America is set to grow from FY27.
Investor Takeaway
- Revenue target of Rs1,000 cr by FY27 represents a roughly 40% jump.
- New product launches (anesthetic APIs, cardiovascular intermediate, ADHD therapy, contrast media) and CDMO contracts add growth drivers.
- Long‑term CDMO deal with DSM could bring up to Rs70 cr per year.
- Strong cash position and no debt give flexibility for further expansion.
Overall, Supriya Lifesciences is positioning itself for faster growth while keeping profitability stable. Investors should watch the progress of the new plants and the rollout of the diversified product line.